Most trials ask whether a new treatment is better. A non-inferiority trial asks whether it is close enough, which is the more useful question when the new treatment is cheaper or easier to deliver. The researchers state the largest acceptable gap before they see any data, and if the interval stays inside it the treatment is non-inferior. It can pass without ever being better.
Drawn from standard trial design, not from this paper.
Time restricted eating is usually tested against a control that receives nothing. This team tested it against the real world alternative, a dietitian, with contact time matched in both arms, and asked whether the window is close enough to serve as a substitute where dietetic support is scarce.
Drawn from the paper's stated aim.
One hundred and twenty four participants randomised to the nine hour self selected eating window with the last eating occasion by seven in the evening, and 123 to individualised dietetic guidance. Two Australian clinical research institutes, staff conducting assessments and analyses blinded to allocation.
Both groups received five personalised telehealth consultations between zero and three months, three hours of contact in total, specific to their allocated group.
Baseline glycated haemoglobin averaged 40 millimoles per mole, which is 5.8 percent, a normal value.
The non-inferiority margin was set in advance at 1.1 millimoles per mole, which is 0.10 percent.
At four months the window was non-inferior but not superior: minus 0.22 millimoles per mole, interval minus 0.72 to 0.30, p equals 0.40.
At twelve months the upper bound of the difference exceeded the margin, so non-inferiority could no longer be concluded: 0.47 millimoles per mole, interval minus 0.19 to 1.23, p equals 0.14.
The authors state that the absolute changes were small and not clinically meaningful in either group at either time point. Adverse events were minor and did not differ between interventions.
| Randomised | 124 to time restricted eating, 123 to individualised dietetic guidance |
| Baseline glycated haemoglobin | 40 mmol/mol, standard deviation 3, which is 5.8 percent |
| Non-inferiority margin, set in advance | 1.1 mmol/mol, or 0.10 percent |
| Four months | minus 0.22 mmol/mol, 95 percent CI minus 0.72 to 0.30, p equals 0.40, non-inferior and not superior |
| Twelve months | 0.47 mmol/mol, 95 percent CI minus 0.19 to 1.23, p equals 0.14, non-inferiority no longer concluded |
| Contact time in both arms | five telehealth consultations, three hours total |
| Eating window | nine hours, self selected, last eating occasion by 19:00 |
| Adverse events | minor and not different between interventions, tracked twelve months |
Proposed by the authors This is the explanation the authors offer in their discussion. This study did not test it.
No physiological mechanism is at issue and the authors propose none. Their framing is about service delivery: a self selected nine hour window finishing before seven in the evening can be taught in a few consultations and then run without professional input, and the question is what that costs in glycaemic control. Their answer at four months is nothing measurable, and at twelve months they say they can no longer make the claim.
Drawn from the authors' stated conclusion.
The eating window held level with a dietitian for four months, and by twelve months the trial could no longer say it was close enough.
Australian adults with overweight or obesity and a raised diabetes risk score, starting from a normal glycated haemoglobin.
The same design in people who actually have elevated glycated haemoglobin, where there is room for either arm to move.
Newsletter
Each issue by email, when the newsletter launches. Leaving your address puts you on the list, nothing is sent yet.